Dividend Win Wednesday: Insiders Add Semiconductors at 40% Off While Energy Sellers Exit at Highs
Top 5 Pixie Picks
Only Pro and Free Trial readers get meta-analysis of the top 5 ranked Dividend stocks.
Sign in →6. Biogen Inc. ([BIIB])
Dividend yield: n/a | Payout ratio: 0% | 52w drawdown: -2%
FCF yield of 6.0% and earnings yield of 4.2% position this as a cash generator trading at a discount to historical normalized earnings, while the lack of a dividend policy leaves $1.7 billion in annual free cash flow available for buybacks or pipeline reinvestment.
⬡ Japan approved an at-home pen delivery system for LEQEMBI (lecanemab) in September, expanding the Alzheimer's franchise into self-administration and removing a major access barrier for patients who avoided clinic infusions, a catalyst that could accelerate adoption rates and extend the drug's commercial runway through 2030.
Insider Michael Parini added exposure on September 3, one of ten insider buys over six months with net positive share accumulation, a rare signal in biotech where management typically hedges rather than adds near all-time highs.
7. Nucor Corporation (NUE)
Dividend yield: 0.9% | Payout ratio: 29% | 52w drawdown: -14%
Normalized P/E of 24 and earnings yield of 4.2% sit near the middle of the steel sector range, while the 14% drawdown offers a cleaner entry than most cyclical industrials trading within 5% of 52-week highs.
FCF yield of -0.3% and net debt to EBITDA of 0.94 signal either working capital expansion or capex intensity, both of which limit the near-term dividend growth runway despite the 29% payout ratio.
One insider sold 185,808 net shares over six months with 100% of activity on the sell side, a pattern that removes this from the high-conviction cyclical recovery bucket despite the drawdown and low payout ratio.
8. Cigna Group (CI)
Dividend yield: 2.3% | Payout ratio: 28% | 52w drawdown: -13%
FCF yield of 11.6% and shareholder yield of 5.0% position this as one of the highest cash-returning health insurers, while the 28% payout ratio leaves 8 percentage points of free cash flow available for buyback acceleration or special distributions.
Normalized earnings yield of 36.5% and P/E of 2.4 suggest either a multi-year earnings trough or accounting noise; revenue growth of 11.7% year-over-year and interest coverage above 6× argue for the former, creating asymmetry if margins stabilize into 2027.
Three insiders added exposure in August and September, including Robert Potashnick, Bruno Guicardi Neto, and Everett Neville, a voting pattern that signals management confidence at current levels despite the 13% drawdown and 24% upside to the $341.50 consensus target.
What to Watch
• October 22–28: Newmont, Novartis, KLA, and Biogen report earnings within a five-day window, a cluster that will clarify whether the drawdown names (KLAC, NVS) can stabilize margins or if the near-high names (BIIB) face compression.
• November 5–6: ConocoPhillips, EOG, and Cigna report on consecutive days, offering a read on energy pricing assumptions and health insurance margin trajectory as year-end guidance season begins.
• Next 30 days: Watch for Form 4 filings from KLA and Biogen insiders; the recent buys suggest conviction, but follow-on purchases would validate the thesis that the drawdowns are temporary rather than structural.
Go Deeper
The dividend screener ranks stocks by FCF yield, payout sustainability, and drawdown depth, then filters for insider alignment and balance-sheet quality.
Check out the full screener →
Pro-only analytics
Named tickers from this article open in the app with Pro or an active trial.
Sign in →Stock Pixie Pro
See the full dividend screen — every pick, every metric, every day.
The app shows up to 10 rows on Free; the top 5 by Pixie rank keep ticker, name, and recent close private. Posts may name the top 5 for context. Pro and trial show every row on the screener, full identifiers, and the rest of Pro.
Start your free trial →Or start with the free Market Brief Digest
Where the market stands before the open, in plain language, every trading day. No account needed.